TomoTherapy Revenue and Competitors

Madison, WI USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • TomoTherapy's estimated annual revenue is currently $27.9M per year.(i)
  • TomoTherapy's estimated revenue per employee is $251,000

Employee Data

  • TomoTherapy has 111 Employees.(i)
  • TomoTherapy grew their employee count by 4% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4M32-6%$50.6MN/A
#2
$18.1M723%N/AN/A
#3
$23.3M937%N/AN/A
#4
$72.5M2890%N/AN/A
#5
$7.3M297%N/AN/A
#6
$28.1M1128%N/AN/A
#7
$104.4M4164%N/AN/A
#8
$12.3M497%N/AN/A
#9
$51.7M2060%N/AN/A
#10
$12.3M499%N/AN/A
Add Company

What Is TomoTherapy?

TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

keywords:N/A

N/A

Total Funding

111

Number of Employees

$27.9M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$11.1M1117%N/A
#2
$18.1M1110%N/A
#3
N/A11213%N/A
#4
$24.6M11213%N/A
#5
$19.6M11211%N/A